Filing · LD-2 quarterly report
Q1 report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 16, 2025
Expenses
$200,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
Virginia
Government bodies contacted
2
Lobbying activity
3
Issues related to the medical-surgical supply chain including domestic and near-shore production including the Pandemic and All-Hazards Preparedness Act (Public Law No. 109-417); Promoting Resilient Supply Chains Act of 2025 (S. 257).
Issues related to patient access to respiratory therapy including non-invasive ventilation and related reimbursement (see the DMEPOS Relief Act of 2025 [H.R. 2005]; the Supplemental Oxygen Access Reform [SOAR] Act of 2024, 118th Congress H.R. 7829, S. 3821); the extension of telehealth flexibilities (see Public Law No. 119-4); and promoting electronic prescribing platforms.
Issues related to the medical-surgical supply chain including domestic and near-shore production.